Last updated on March 2019

Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung Cancer


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: malignant pleural effusion | Non-small Cell Carcinoma
  • Age: Between 20 - 79 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Age 20, and NSCLC patients with malignant pleural effusion and related symptoms
  • ECOG 2
  • Blood test ANC 1500/mm3, Hb 8.0g/dl, platelet count 100000/mm3 Serum creatinine 1.8mg/dl, Total bilirubin within normal limits, Transaminases 1.5 x UNL, Alkaline phosphatase 2.5 X UNL BUN 25mg/dl, Creatinine clearance 50ml/min
  • Negative serum or urine pregnancy test for women for childbearing age
  • Patients who provide written informed consent for the study

Exclusion Criteria:

  • Age < 20
  • Patients who were previously perfomed pleurodesis
  • Patients who were previously treated with thoracic radiosurgery
  • Patinet with bilateral pleural effusion
  • Age 80yrs
  • Patients with histories of hypersensitivity to Docetaxel
  • Patients with cardiovascular, respiratory, hepatic, renal, gastrointestinal, neunological disease, asthma, MI, stroke, arrhythmia, uncontrolled hypertionsion, etc. that would effect absorption, distribution, and metabolism of IP or be risk factors during IP administrion.
  • Patients who could not understand the study procedure

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.